Education
About Us
Working with TipRanks
Follow Us
Knight Therapeutics (TSE:GUD)
TSX:GUD
Total Valuation
Knight Therapeutics has a market cap or net worth of C$540.38M. The enterprise value is C$441.39M.
Market CapC$540.38M
Enterprise ValueC$441.39M
Share Statistics
Knight Therapeutics has 99.52M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding99.52M
Owened by Insiders35.20%
Owened by Instutions0.09%
Financial Efficiency
Knight Therapeutics’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per EmployeeC$467,969.128
Profits Per Employee-C$41,246.98
Employee Count745
Asset Turnover0.35
Inventory Turnover1.91
Valuation Ratios
The current PE Ratio of Knight Therapeutics is -33.13. Knight Therapeutics’s PEG ratio is 0.86.
PE Ratio-33.13
PS Ratio1.70
PB Ratio0.75
Price to Fair Value0.75
Price to FCF21.47
Price to Operating Cash Flow15.52
PEG Ratio0.86
Income Statement
In the last 12 months, Knight Therapeutics had revenue of C$348.64M and earned -C$30.73M in profits. Earnings per share was -C$0.30.
RevenueC$348.64M
Gross ProfitC$134.61M
Operating IncomeC$10.33M
Pretax Income-C$31.98M
Net Income-C$30.73M
EBITDA30.98M
Earnings Per Share (EPS)-0.30
Cash Flow
In the last 12 months, operating cash flow was C$43.06M and capital expenditures -C$32.18M, giving a free cash flow of C$11.98M billion.
Operating Cash FlowC$43.06M
Free Cash FlowC$11.98M
Free Cash Flow per ShareC$0.12
Dividends & Yields
Knight Therapeutics pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.26
52-Week Price Change-2.95%
50-Day Moving Average5.78
200-Day Moving Average5.63
Relative Strength Index (RSI)61.90
Average Volume (3m)106.75K
Important Dates
Knight Therapeutics upcoming earnings date is May 8, 2025, Before Open.
Last Earnings DateMar 20, 2025
Next Earnings DateMay 8, 2025
Ex-Dividend Date―
Financial Position
Knight Therapeutics as a current ratio of 3.20, with Debt / Equity ratio of 0.09
Current Ratio3.20
Quick Ratio2.40
Debt to Market Cap0.11
Net Debt to EBITDA―
Interest Coverage Ratio-0.23
Taxes
In the past 12 months, Knight Therapeutics has paid -C$1.25M in taxes.
Income Tax-C$1.25M
Effective Tax Rate23.44%
Enterprise Valuation
Knight Therapeutics EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
Knight Therapeutics has C$172.32M in cash and marketable securities with C$58.22M in debt, giving a net cash position of -C$114.10M billion.
Cash & Marketable SecuritiesC$172.32M
Total DebtC$58.22M
Net Cash-C$114.10M
Net Cash Per Share-C$1.15
Tangible Book Value Per ShareC$3.51
Margins
Gross margin is 46.51%, with operating margin of -0.88%, and net profit margin of -5.13%.
Gross Margin46.51%
Operating Margin-0.88%
Pretax Margin-6.70%
Net Profit Margin-5.13%
EBITDA Margin12.46%
EBIT Margin-2.89%
Analyst Forecast
The average price target for Knight Therapeutics is C$7.94, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price TargetC$7.94
Price Target Upside42.05%
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast13.13%
EPS Growth Forecast